Ceeto Capital Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.11M | Buy |
20,290
+10
| +0% | +$2.15K | 1.38% | 12 |
|
|
2026
Q1 | $4.41M | Buy |
20,280
+810
| +4% | +$180K | 1.35% | 13 |
|
|
2025
Q4 | $4.45M | Buy |
19,470
+7
| +0% | +$1.59K | 1.3% | 12 |
|
|
2025
Q3 | $4.51M | Buy |
19,463
+11
| +0.1% | +$2.24K | 1.31% | 11 |
|
|
2025
Q2 | $3.61M | Buy |
19,452
+360
| +2% | +$66.9K | 1.26% | 13 |
|
|
2025
Q1 | $4M | Buy |
19,092
+10
| +0.1% | +$1.94K | 1.52% | 9 |
|
|
2024
Q4 | $3.39M | Buy |
19,082
+210
| +1% | +$38.6K | 1.25% | 13 |
|
|
2024
Q3 | $3.73M | Sell |
18,872
-1,790
| -9% | -$334K | 1.39% | 10 |
|
|
2024
Q2 | $3.54M | Buy |
20,662
+11
| +0.1% | +$1.82K | 1.37% | 11 |
|
|
2024
Q1 | $3.76M | Buy |
20,651
+11
| +0.1% | +$1.9K | 1.54% | 10 |
|
|
2023
Q4 | $3.2M | Buy |
20,640
+12
| +0.1% | +$1.75K | 1.37% | 10 |
|
|
2023
Q3 | $3.08M | Buy |
20,628
+1,710
| +9% | +$251K | 1.49% | 8 |
|
|
2023
Q2 | $2.55M | Buy |
18,918
+12
| +0.1% | +$1.76K | 1.17% | 12 |
|
|
2023
Q1 | $3.01M | Buy |
18,906
+10
| +0.1% | +$1.53K | 1.5% | 7 |
|
|
2022
Q4 | $3.05M | Buy |
18,896
+62
| +0.3% | +$9.51K | 1.68% | 6 |
|
|
2022
Q3 | $2.53M | Buy |
18,834
+10
| +0.1% | +$1.44K | 1.45% | 6 |
|
|
2022
Q2 | $2.88M | Buy |
18,824
+10
| +0.1% | +$1.53K | 1.58% | 6 |
|
|
2022
Q1 | $3.05M | Sell |
18,814
-489
| -3% | -$71K | 1.39% | 10 |
|
|
2021
Q4 | $2.61M | Buy |
19,303
+11
| +0.1% | +$1.3K | 1.09% | 14 |
|
|
2021
Q3 | $2.08M | Sell |
19,292
-6,488
| -25% | -$741K | 0.97% | 23 |
|
|
2021
Q2 | $2.9M | Buy |
25,780
+11
| +0% | +$1.24K | 1.31% | 10 |
|
|
2021
Q1 | $2.79M | Buy |
25,769
+163
| +0.6% | +$17.4K | 1.36% | 11 |
|
|
2020
Q4 | $2.74M | Buy |
25,606
+706
| +3% | +$67.8K | 1.38% | 10 |
|
|
2020
Q3 | $2.18M | Buy |
24,900
+3,134
| +14% | +$295K | 1.22% | 13 |
|
|
2020
Q2 | $2.14M | Buy |
21,766
+1,866
| +9% | +$164K | 1.38% | 12 |
|
|
2020
Q1 | $1.52M | Buy |
19,900
+900
| +5% | +$76.7K | 1.22% | 19 |
|
|
2019
Q4 | $1.68M | Hold |
19,000
| – | – | 1.1% | 22 |
|
|
2019
Q3 | $1.44M | Sell |
19,000
-1,000
| -5% | -$68.6K | 1.04% | 25 |
|
|
2019
Q2 | $1.45M | Buy |
20,000
+2,000
| +11% | +$157K | 1.07% | 26 |
|
|
2019
Q1 | $1.45M | Buy |
18,000
+500
| +3% | +$40.9K | 1.06% | 28 |
|
|
2018
Q4 | $1.61M | Hold |
17,500
| – | – | 1.33% | 17 |
|
|
2018
Q3 | $1.66M | Buy |
17,500
+1,500
| +9% | +$142K | 1.14% | 19 |
|
|
2018
Q2 | $1.48M | Hold |
16,000
| – | – | 1.11% | 22 |
|
|
2018
Q1 | $1.51M | Hold |
16,000
| – | – | 1.15% | 21 |
|
|
2017
Q4 | $1.55M | Hold |
16,000
| – | – | 1.11% | 23 |
|
|
2017
Q3 | $1.42M | Buy |
+16,000
| New | +$1.22M | 1.07% | 24 |
|
Other funds holding ABBV
Ceeto Capital Group's ABBV Position: Q2 2026 in Review
Ceeto Capital Group increased its AbbVie (ABBV) stake by 0.05% in Q2 2026, buying an estimated $2.15K and bringing the position to 20,290 shares worth $5.11M. The position accounts for 1.38% of the portfolio, ranked #12.
Ceeto Capital Group first reported a position in ABBV in Q3 2017 and has held it in 36 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Ceeto Capital Group held 20,290 shares of AbbVie worth $5.11M as of Q2 2026.
- Ceeto Capital Group bought 10 AbbVie shares in Q2 2026, an estimated $2.15K.
- AbbVie made up 1.38% of Ceeto Capital Group's portfolio in Q2 2026, its #12 holding.
- Ceeto Capital Group first reported a position in AbbVie in Q3 2017 and has held it in 36 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Ceeto Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.